FY2025 EPS Estimates for Precigen Cut by Cantor Fitzgerald

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Precigen in a research note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst J. Kim now anticipates that the biotechnology company will earn ($0.37) per share for the year, down from their prior forecast of ($0.27). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

Separately, HC Wainwright reissued a "buy" rating and set a $6.00 price objective on shares of Precigen in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Precigen has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Precigen Trading Up 10.7%

Precigen stock opened at $1.45 on Monday. The firm has a market capitalization of $427.99 million, a P/E ratio of -2.64 and a beta of 1.82. The business has a 50-day moving average of $1.50 and a 200-day moving average of $1.30. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17.

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The business had revenue of $1.34 million during the quarter, compared to the consensus estimate of $0.50 million.

Institutional Trading of Precigen

Hedge funds have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. grew its stake in Precigen by 3.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock valued at $16,801,000 after acquiring an additional 410,595 shares during the period. Iridian Asset Management LLC CT raised its position in shares of Precigen by 38.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock worth $5,871,000 after purchasing an additional 1,465,962 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company's stock valued at $3,696,000 after purchasing an additional 53,343 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in shares of Precigen during the 1st quarter valued at about $4,755,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Precigen by 4.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company's stock valued at $1,432,000 after purchasing an additional 56,012 shares during the period. Institutional investors and hedge funds own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.